Home | Welcome to Contract Pharma   
Last Updated Wednesday, April 16 2014
Print

Aridis Acquires Kenta mAb Portfolio



Published May 17, 2013
Related Searches: Development
Aridis has entered an agreement with Kenta Biotech to acquire Kenta's portfolio of anti-infective human monoclonal antibody (mAb) products and technologies. The portfolio includes six anti-infectives for the treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and respiratory syncytial virus (RSV). Two candidates are in Phase IIa trials for acute pneumonia.
 
Aridis founder and president Eric Patzer said, "We are pleased to complete this transaction and build upon the substantial financial investment and remarkable progress that our colleagues at Kenta Biotech have achieved in creating a portfolio of innovative products.”
 
Kenta chief executive officer Franco Merckling said, "We are pleased to have identified Aridis as the ideal partner to further develop the Kenta technology and project pipeline which has been built over the last seven years. Aridis, a leading San Francisco-area biotech company specializing in novel anti-infectives, is poised to accelerate the development of our drug candidates in both the U.S. and Europe.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On